Search research articles
Contact Us
Filters
Showing results (221-230 of 264) with videos related to
Page
of 27
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
February 27, 2018
Ultra-early response assessment in lymphoma treatment: [<sup>18</sup>F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
Marius E Mayerhoefer, Markus Raderer, Ulrich Jaeger, et al.
Blood
|
November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial
Andrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
The New England Journal of Medicine
|
July 12, 2014
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Hematological Oncology
|
July 9, 2015
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, et al.
Endocrine-Related Cancer
|
January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
British Journal of Haematology
|
March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
Annarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2015
Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients
Marius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Journal of Personalized Medicine
|
October 29, 2020
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI
Hossein Taghizadeh, Matthias Unseld, Martina Spalt, et al.
ESMO Open
|
August 20, 2019
Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
Markus Kieler, Matthias Unseld, Daniela Bianconi, et al.
Anti-Cancer Drugs
|
January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Tal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 264) with videos related to
Sort By:
Page
of 27
European Journal of Nuclear Medicine and Molecular Imaging
|
February 27, 2018
Ultra-early response assessment in lymphoma treatment: [<sup>18</sup>F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
Marius E Mayerhoefer, Markus Raderer, Ulrich Jaeger, et al.
Blood
|
November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial
Andrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
The New England Journal of Medicine
|
July 12, 2014
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Hematological Oncology
|
July 9, 2015
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, et al.
Endocrine-Related Cancer
|
January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
British Journal of Haematology
|
March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
Annarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2015
Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients
Marius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Journal of Personalized Medicine
|
October 29, 2020
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI
Hossein Taghizadeh, Matthias Unseld, Martina Spalt, et al.
ESMO Open
|
August 20, 2019
Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
Markus Kieler, Matthias Unseld, Daniela Bianconi, et al.
Anti-Cancer Drugs
|
January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Tal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.
Page
of 27